Spire Wealth Management Boosts Stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Spire Wealth Management boosted its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 9,919.0% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 14,227 shares of the biopharmaceutical company's stock after buying an additional 14,085 shares during the quarter. Spire Wealth Management's holdings in Halozyme Therapeutics were worth $908,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also bought and sold shares of the company. CBIZ Investment Advisory Services LLC purchased a new stake in shares of Halozyme Therapeutics in the fourth quarter worth approximately $29,000. Heck Capital Advisors LLC bought a new position in Halozyme Therapeutics in the 4th quarter valued at $29,000. Smartleaf Asset Management LLC increased its stake in Halozyme Therapeutics by 29.2% in the fourth quarter. Smartleaf Asset Management LLC now owns 871 shares of the biopharmaceutical company's stock worth $42,000 after purchasing an additional 197 shares during the period. UMB Bank n.a. increased its stake in Halozyme Therapeutics by 267.4% in the first quarter. UMB Bank n.a. now owns 1,319 shares of the biopharmaceutical company's stock worth $84,000 after purchasing an additional 960 shares during the period. Finally, Parkside Financial Bank & Trust lifted its position in shares of Halozyme Therapeutics by 21.8% during the fourth quarter. Parkside Financial Bank & Trust now owns 1,800 shares of the biopharmaceutical company's stock worth $86,000 after purchasing an additional 322 shares during the last quarter. Institutional investors own 97.79% of the company's stock.

Analyst Upgrades and Downgrades

HALO has been the topic of a number of research analyst reports. Leerink Partnrs cut shares of Halozyme Therapeutics from a "hold" rating to a "strong sell" rating in a report on Tuesday, May 13th. HC Wainwright restated a "buy" rating and issued a $72.00 target price on shares of Halozyme Therapeutics in a research note on Thursday, May 29th. Leerink Partners downgraded shares of Halozyme Therapeutics from a "market perform" rating to an "underperform" rating and set a $47.00 price target for the company. in a research note on Tuesday, May 13th. JPMorgan Chase & Co. increased their price objective on Halozyme Therapeutics from $55.00 to $58.00 and gave the stock a "neutral" rating in a research note on Monday, April 21st. Finally, Benchmark downgraded Halozyme Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Wednesday, May 7th. Two equities research analysts have rated the stock with a sell rating, six have issued a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, Halozyme Therapeutics has an average rating of "Hold" and a consensus target price of $61.90.

Halozyme Therapeutics Stock Up 1.7%

Halozyme Therapeutics stock traded up $0.90 during mid-day trading on Tuesday, reaching $52.92. 2,150,463 shares of the company were exchanged, compared to its average volume of 1,747,347. The firm has a market cap of $6.52 billion, a P/E ratio of 14.07, a PEG ratio of 0.35 and a beta of 1.15. The company has a debt-to-equity ratio of 3.13, a quick ratio of 7.30 and a current ratio of 8.39. Halozyme Therapeutics, Inc. has a 12-month low of $42.01 and a 12-month high of $70.51. The business has a fifty day moving average of $55.81 and a 200 day moving average of $56.51.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The biopharmaceutical company reported $1.11 earnings per share for the quarter, beating analysts' consensus estimates of $0.98 by $0.13. The company had revenue of $264.86 million for the quarter, compared to the consensus estimate of $231.21 million. Halozyme Therapeutics had a return on equity of 136.91% and a net margin of 44.76%. The firm's revenue for the quarter was up 35.2% compared to the same quarter last year. During the same quarter last year, the company earned $0.79 earnings per share. Research analysts anticipate that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

Insider Buying and Selling at Halozyme Therapeutics

In other news, CEO Helen Torley sold 20,000 shares of the firm's stock in a transaction on Tuesday, June 24th. The stock was sold at an average price of $53.73, for a total value of $1,074,600.00. Following the completion of the sale, the chief executive officer owned 733,719 shares of the company's stock, valued at $39,422,721.87. This trade represents a 2.65% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Jeffrey William Henderson sold 4,497 shares of the company's stock in a transaction dated Monday, April 28th. The shares were sold at an average price of $60.37, for a total value of $271,483.89. Following the transaction, the director directly owned 28,611 shares in the company, valued at $1,727,246.07. This represents a 13.58% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 44,497 shares of company stock valued at $2,405,284. Company insiders own 2.90% of the company's stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.